A Study of KK2269 in Adult Participants With Solid Tumors
← catalyst calendarNCT06266299 · readout ≤ 954 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →. With Kyowa Kirin, Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
101estimated
Sites
11
Countries
Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-18 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Non Small Cell Lung Cancer
Interventions
- Drug: KK2269
- Drug: Docetaxel — also filed as Docetaxel Hydrate
Primary outcomes
what the primary-completion date above is the date OFNumber of Subjects Experiencing Dose-limiting Toxicity
measured 21 days after first dose
Number of Adverse Events
measured From signing of ICF through study completion, an average of 1 year
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed